Evaluation of a newer (1, 3)-β-D-glucan chemiluminescent immunoassay for invasive candidiasis: A study from a tertiary care center.

Abstract

Background and purpose: Invasive candidiasis (IC) in the hospitalized population is one of the leading causes of invasive fungal infections (IFIs). Microbiological diagnosis of IC suffers due to poor sensitivity of blood culture and relative inaccessibility to more sensitive modalities. (1, 3)-β-D-glucan (BDG) is a cell wall polysaccharide found in a range of fungi. Various commercial assays are available based on various detection techniques. This study aimed to assess the diagnostic performance of the FungiXpert® Fungus BDG Detection Kit by Genobio Pharmaceutical Co. Ltd. (Tianjin, China), based on chemiluminescent method, for diagnosis of candidemia and deep-seated candidiasis.

Materials and methods: In total, 80 patients (34 males and 46 females) were included with a median age of 35 years old. In accordance with EORTC/MSGERC definitions, 39 patients had proven IC. The number of patients within the probable, possible, and no IC (taken as control) groups were 8, 4, and 29, respectively. Blood samples were collected for fungal blood culture and BDG assay.

Results: After exclusion of cases with evidence of concurrent IFI other than IC, median serum BDG was 0.63 ng/ml for proven IC; while it was 0.04 ng/ml for NO IC. Sensitivity, specificity, positive, and negative predictive values were 60.52%, 81.81%, 85.18%, and 54.54%, respectively. Positive likelihood ratio was 3.32. While the assay performed best for Candida tropicalis with median BDG of 1.92 ng/ml and sensitivity of 92.3%, its performance was worst for Candida parapsilosis, with median BDG of 0.04 ng/ml and sensitivity of 44.44%. Overall mortality rate was 65.62% in the BDG positive group, which was significantly higher than that in the BDG negative group (33.33%).

Conclusion: The performance of the FungiXpert® Fungus BDG Detection Kit was acceptable for invasive candidiasis in the present resource-limited setup. The major advantages of this assay were the ease of performance in a semi-automated cartridge format, relatively lower cost per test, non-reliance on glucan-free procedures or instruments and minimal hands-on procedure.